This is the classic website, which will be retired eventually. Please visit the modernized instead.
Working… Menu

Phase 1 Study to Evaluate the Safety and Tolerability of VK2735

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT05203237
Recruitment Status : Recruiting
First Posted : January 24, 2022
Last Update Posted : September 14, 2023
Information provided by (Responsible Party):
Viking Therapeutics, Inc.

Brief Summary:
This is a Phase 1, randomized, double-blind, placebo-controlled single and multiple ascending dose study to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of VK2735 in healthy adults and otherwise healthy adults who have an increased body mass index (BMI).

Condition or disease Intervention/treatment Phase
Weight Loss NASH Biological: VK2735 Biological: Placebo Drug: VK2735 Placebo Drug: VK2735 Drug Phase 1

Detailed Description:

This study comprises 3 parts:

Part A (Single Ascending Dose [SAD]) will be conducted to assess the safety, tolerability, and PK profile in healthy participants following 1 single SC injection of VK2735 or VK2735 matching placebo (SAD Cohort 1 through SAD Cohort 6).

Part B (Multiple Ascending Dose [MAD]) will be conducted to assess the safety, tolerability, PK and PD profile in otherwise healthy participants who have an increased BMI following single SC injections of VK2735 or matched placebo administered once weekly for 4 consecutive weeks (MAD Cohort 1 through MAD Cohort 5).

Part C (Multiple Ascending Dose [MAD], PO) will be conducted to assess the safety, tolerability, PK and PD profiles in otherwise healthy, but obese, participants who have a BMI ≥30 kg/m2 following daily oral administration of VK2735 or matched placebo administered for 28 consecutive days (MAD-PO Cohort 1 through MAD-PO Cohort 4, with optional additional cohorts)

Safety Review Committee (SRC) meetings will be held prior to dose escalation for Part A (SAD), Part B (MAD), and Part C (MAD-PO) cohorts in the study. The decisions on dose escalation will be based on safety and laboratory data from each cohort.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 136 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Official Title: A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of VK2735, a Dual Glucagon-like Peptide-1 and Gastric Inhibitory Polypeptide Receptor Agonist, in Healthy Adults and Otherwise Healthy Adults Who Have an Increased Body Mass Index
Actual Study Start Date : December 14, 2021
Estimated Primary Completion Date : November 2023
Estimated Study Completion Date : December 2023

Arm Intervention/treatment
Placebo Comparator: Placebo (Part A)
Placebo administered SC once in healthy participants
Biological: Placebo
Administered SC

Experimental: VK2735 (Part A)
Escalating doses of VK2735 administered subcutaneously (SC) once in healthy participants.
Biological: VK2735
Administered SC

Placebo Comparator: Placebo (Part B)
Placebo administered SC once weekly for four weeks in healthy participants
Biological: Placebo
Administered SC

Experimental: VK2735 (Part B)
Escalating doses of VK2735 administered subcutaneously (SC) once weekly in healthy participants.
Biological: VK2735
Administered SC

Placebo Comparator: VK2735 (Part C )
Placebo administered orally daily for 28 days in healthy participants
Drug: VK2735 Placebo
Administered orally

Experimental: VK2735 (Part C)
Escalating doses of VK2735 administered daily (PO) in healthy participants.
Drug: VK2735 Drug
Administered orally

Primary Outcome Measures :
  1. Incidence of treatment-emergent adverse events (TEAEs) and treatment-emergent serious AEs (TESAEs) [ Time Frame: 8 days ]
    To evaluate the safety and tolerability of single doses of subcutaneous injections of VK2735 in healthy participants

Secondary Outcome Measures :
  1. Evaluate the Pharmacokinetic profile of VK2735 [ Time Frame: 29 days ]
    Pharmacokinetic profile of VK2735 by measuring peak plasma concentration (Cmax)

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 65 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

Participants must be capable of giving signed informed consent

Participants must be medically healthy, with no significant medical history, have no clinically significant abnormalities on physical examination at Screening and/or before administration of the initial dose of IP in the opinion of the Investigator

Participant body weight must have been stable (no change greater than 5%) for a minimum 8 weeks prior to Screening

Willing and able to comply with scheduled visits, treatment plan, laboratory tests and other clinical study procedures

Willing to comply with contraception requirements

Exclusion Criteria:

Participants with any level of disease or organ system dysfunction as identified during physical examination, medical history or laboratory testing, as assessed by the PI

Any surgical or medical condition (active or chronic) that may interfere with IP distribution, metabolism, excretion, or drug absorption

Participants may be excluded from the study if they have conditions that might compromise safety or other endpoints in the study as judged by the Sponsor (or designee) or Investigator

History or presence of clinically significant acute or unstable cerebrovascular (stroke), hepatic, renal, gastrointestinal, pulmonary, immunological, endocrine, diabetes, hematological, oncological, or central nervous disorder that in the opinion of the Investigator would pose a significant risk for the participant

Use of any investigational drug or product, or participation in an investigational drug study within 30 days prior to dosing or 5 half-lives of the drug (whichever is longest)

Active smoker and/or user of nicotine-containing products unless the participant agrees to discontinue smoking/use of nicotine-containing products from 2 weeks before first IP dose administration through to study completion, including the Follow-up period

Have serum triglycerides > 5.65 mmol/L (500 mg/dL) at Screening

Positive serology for hepatitis B surface antigen (HBsAg), hepatitis C antibodies, or HIV

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT05203237

Layout table for location contacts
Contact: Marianne Mancini 858-704-4674
Contact: Becky Steele 858-704-4687

Layout table for location information
Australia, South Australia
Viking Clinical Site Recruiting
Adelaide, South Australia, Australia, 5000
Sponsors and Collaborators
Viking Therapeutics, Inc.
Layout table for investigator information
Study Director: Marianne Mancini Viking Therapeutics, Inc.
Layout table for additonal information
Responsible Party: Viking Therapeutics, Inc. Identifier: NCT05203237    
Other Study ID Numbers: VK2735-101
First Posted: January 24, 2022    Key Record Dates
Last Update Posted: September 14, 2023
Last Verified: September 2023
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Weight Loss
Body Weight Changes
Body Weight